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Abstract
Bcr-Abl inhibitors paved the way of targeted therapy epoch. Imatinib was the first tyrosine kinase inhibitor to be
discovered with high specificity for Bcr-Abl protein resulting from t(9, 22)-derived Philadelphia chromosome. Although
the specific targeting of that oncoprotein, several Bcr-Abl-dependent and Bcr-Abl-independent mechanisms of
resistance to imatinib arose after becoming first-line therapy in chronic myelogenous leukemia (CML) treatment.
Consequently, new specific drugs, namely dasatinib, nilotinib, bosutinib, and ponatinib, were rationally designed and
approved for clinic to override resistances. Imatinib fine mechanisms of action had been elucidated to rationally
develop those second- and third-generation inhibitors. Crystallographic and structure-activity relationship analysis,
jointly to clinical data, were pivotal to shed light on this topic. More recently, preclinical evidence on bafetinib,
rebastinib, tozasertib, danusertib, HG-7-85-01, GNF-2, and 1,3,4-thiadiazole derivatives lay promising foundations for
better inhibitors to be approved for clinic in the near future.
Notably, structural mechanisms of action and drug design exemplified by Bcr-Abl inhibitors have broad relevance to
both break through resistances in CML treatment and develop inhibitors against other kinases as targeted
chemotherapeutics.
Keywords: Bcr-Abl, Structure-activity relationship, Leukemia, Targeted therapy, Tyrosine kinase inhibitors (TKIs), Imatinib,
Dasatinib, Nilotinib, Bosutinib, Ponatinib
Background
The vast majority of chronic myelogenous leukemia
(CML) cases and 20–30% of those of acute lympho-
blastic leukemia (ALL) are caused by a reciprocal
chromosomal translocation between chromosome 9 and
22—t(9, 22)—thus forming the so-called Philadelphia
chromosome (Ph) [1]. The product of this genetic re-
arrangement consists in Bcr-Abl fusion protein with
deregulated tyrosine kinase activity that leads immune
precursors to divide endlessly. That was the first innova-
tive prove of a disease to be caused and marked by an
acquired chromosomal translocation.
As the fusion protein was recognized to be the
primum movens of those leukemias in the 1980s, the
therapeutic effort was directed towards that specific tar-
get, trying to emulate the successful breakthrough of
tamoxifen in breast cancer, the very first “targeted ther-
apy” [2]. Imatinib (STI571) was therefore discovered as
the first selective Bcr-Abl tyrosine kinase inhibitor (TKI)
by means of drug screening approach [3, 4].
Despite the increase in overall survival allowed by ima-
tinib [5], drug resistance onset led scientists to investi-
gate imatinib fine structural mechanism of action to
develop new and more effective compounds against mu-
tated forms of Bcr-Abl. Most of resistances rely on
Bcr-Abl aminoacidic substitutions, mainly within the
kinase domain. One of the most frequent mutations,
ranging from 2 to 20% of CML cases [6], is T315I (iso-
leucine replaces threonine in position 315 of Bcr-Abl),
which is also the deadliest case since it leads to resist-
ance to second-generation TKIs, such as nilotinib and
dasatinib [7, 8]. Only with the advent of ponatinib has it
been possible to overcome that further therapeutic
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hurdle [9]. Therefore, Bcr-Abl inhibitors represent a
model for paving the way towards the development of
new small molecules for targeted therapy.
Here, we review the rational development of the latter
TKIs that allow the already-high CML survival to be-
come even higher, approaching totality of cases [10].
Specific in vitro potency of TKIs will be compared in
term of IC50 in cell proliferation assays testing target ki-
nases (50% inhibitory concentration (IC50)is defined as
the drug concentration resulting in 50% cell growth in-
hibition that corresponds to the fraction affected of 0.5).
IC50 values of the debated TKIs are summarized in
Table 1. Clinical effects will instead be reported accord-
ingly to the end points of the most authoritative trials
on the subject.
Main text
Structural data of Bcr-Abl fusion protein
Crystallographic analysis of Bcr-Abl protein highlights a
two-lobe catalytic domain: N- and C-lobes towards N-
and C-terminus of the sequence, respectively (Fig. 1).
β-Sheets compose the former, whereas α-helices prevail
in the latter. An important Wolker loop (also known as
phosphate-binding or P-loop) links two β-sheets of
N-lobe. Thanks to its high flexibility, a P-loop residue
can interpose between β- and γ-phosphates of bound ad-
enosine triphosphate (ATP), thus promoting phosphoric
anhydride bond break after nucleophilic attack from
Asp363 of the so-called catalytic loop [11]. The hinge re-
gion, which links the two lobes, also participates in ATP
binding by two hydrogen bonds. Within the
ATP-binding pocket, a “gatekeeper” residue, Thr315, in-
teracts with ATP, too; furthermore, it plays a key role in
conferring selectivity to some of the Bcr-Abl inhibitors.
Indeed, Thr315 is located at the peak of one of the mul-
tiple hydrophobic “spikes” connecting C- and N-lobes in
active conformation [12].
At one portion of the C-lobe, a pivotal loop with regu-
latory function stems out. Thanks to its mobility, this
“activation loop” can alter its conformation to activate
and inactivate the kinase. On a structural point of view,
the activation loop has in turn three key portions: a
DFG (Asp-Phe-Gly) motif at the N-terminus, a central
tyrosine residue (Tyr393), and the peptide
substrate-binding C-terminus [11]. During active phase,
the former contributes with its Asp381 residue in coord-
inating Mg2+ ions, key cofactors of catalysis, whereas the
latter accommodates the peptide substrate to be phos-
phorylated. Tyr393, instead, is the Abl target residue
whose phosphorylation leads to loop extension and as-
sumption of kinase active conformation. This conform-
ation shows a high grade of similarity among various
kinase families, thus justifying the greater number of
TKIs developed towards the conversely more
characteristic inactive conformation. In fact, the latter
conformation displays the activation loop folding in to-
wards ATP-binding site, hence avoiding ATP entrance.
This arrangement dislocates the DFG motif out of the
catalytic site (here the name “DFG-out” conformation)
and prevents Mg2+-mediated catalysis. Conversely, the
active conformation is also known as “DFG-in,” since
the activation loop protrudes out from the ATP-binding
pocket, confining DFG motif inside the catalytic site.
While the latter conformation is shared by different ki-
nases, the former defines a peculiar site among the dislo-
cated activation loop, the gatekeeper residue, and the
C-lobe, which has been set as the main target in the de-
velopment of specific TKIs [13].
Counterintuitively, even if the chimeric oncoprotein is
known to be hyperactive to cause leukemia, after each
substrate phosphorylation step, the Asp363 residue gets
transiently protonated (Fig. 2), leading to conformational
changes and a consequent inactivation, which allows in-
hibitor binding. This represents the reason why the
DFG-out inhibitors are effective despite the kinase
hyperactivity in the tumor. As previously told, the
Thr315 residue is pivotal in stabilizing active conform-
ation: its replacement by isoleucine (T315I) prevents
conformational changes to inactive form, therefore con-
ferring resistance to several DFG-out inhibitors [12].
First-generation inhibitor: imatinib
In the early 1990s, a screening for protein kinase C
(PKC) inhibitors was carried out and led to the identifi-
cation of a phenylaminopyrimidine derivative as poten-
tial lead compound with high prospective for diversity,
allowing simple chemistry to produce more potent and
selective molecules against several kinases [14]. At first,
a pyridyl group was added at the 3′-position of the pyr-
imidine to boost its cellular activity. Various functional
groups were then tested as substituents in the phenyl
ring, until the presence of an amide group was found to
confer inhibitory action against tyrosine kinases. Fur-
thermore, analysis of structure-activity relationships evi-
denced that a substitution in position 6 of the
diaminophenyl ring abolished the activity against PKC.
Conversely, the addition of a methyl group in an ortho
position to the amino group increased selectivity for
Bcr-Abl. However, the resulting molecule still showed
poor oral bioavailability and solubility in water, which
were considerably improved by the introduction of an
N-methylpiperazine group. Nevertheless, in spite of the
abovementioned improvements and of the increased af-
finity of the resulting molecule for its target, the
N-methlypiperazine addition would have generated an
aniline moiety in the structure. To abolish its mutagenic
potential, the abovementioned amide group and a spacer
benzene ring were introduced [14]. These structural
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developments led to the production of imatinib (STI571)
(Fig. 3), the first known ATP competitor able to inhibit
Bcr-Abl kinase with high selectivity (but not absolute
specificity: wild-type (WT) platelet-derived growth factor
receptor (PDGFR) and c-Kit are inhibited, too, as
demonstrated by similar IC50 values of approximately
100–150 nM for all three kinases [15], see Table 1) and
to be approved in the clinics in 2001, less than a decade
later its experimental production [5, 16]. Docking stud-
ies and X-ray crystallography evidence that imatinib in-
teracts with its target through binding the hinge region
in its entire width [17].
Imatinib consists in a typical bisarylanilino core com-
prising a phenyl ring on one side and a
pyridine-pyrimidine moiety on the other side, possessing
a benzamide-piperazine group in the meta-position of
the aniline-type nitrogen atom (Fig. 3). The core
interacts with gatekeeper Thr315 through both hydrogen
bond (H-b) and Van der Waals (VdW) interactions. The
two substituents, instead, are splayed at about 120°, fit-
ting the adenine-binding site and the abovementioned
peculiar site of the DFG-out conformation, respectively.
The former is shielded from the solvent in a hydropho-
bic cage delimited by Tyr253 of the P-loop (which is
kinked during the inactive phase), Phe382 of the activa-
tion loop, together with Leu248, Phe317 and Leu370 res-
idues; the latter preeminently establishes VdW
interactions with the following Bcr-Abl residues: Val289
and Met290 of the C-lobe, Asp381 of the DFG motif,
and Ile360 and His361 of the catalytic loop [11].
Overall, the majority of imatinib interactions are of weak
VdW type, but also six highly energetic H-bs take place:
each of these accounts for a relative high portion of the
total binding energy of the complex kinase-inhibitor, thus
providing a theoretical explanation for resistance due to
mutations of H-b donor/acceptor residues. In fact, if one
of these bonds and consequently its energetic contribution
gets lost, free energy of dissociated state becomes highly
competitive against that of the bound state, thus justifying
the missed interaction between imatinib and the mutated
kinase due to less favorable thermodynamic factors: that
underlies resistance.
Mechanisms of resistance to imatinib
Imatinib treatment fails in approximately one third of pa-
tients [18]. Underlying mechanisms of resistance are clas-
sically divided into two types: Bcr-Abl-dependent and
Bcr-Abl-independent mechanisms. The latter consists
mainly in increased drug efflux/decreased uptake and acti-
vation of alternative onco-pathways. The former, instead,
are mainly due to point mutations of Bcr-Abl that alter in-
hibitor binding or conformational changes; nevertheless, a
residual amount of Bcr-Abl-dependent resistances are also
due to gene amplification or hyperexpression [19].
Since the vast majority of cases are due to point muta-
tions, new inhibitors have been developed with a rational
drug design approach aimed at overriding resistances by
loosening conformational and binding requirements with-
out losing specificity. Second-generation inhibitors solve
almost the entirety of mutations except for T315I. The
substitution of the gatekeeper residue frustrates the action
of inhibitors through two potent mechanisms: break of a
H-b and strong stabilization of the active DFG-in con-
formation. This consistent obstacle has been overcome
only thanks to third-generation inhibitors [20].
Clinically approved second-generation inhibitors
In order to break through mutations, several
second-generation TKIs have been developed and
approved for clinics, i.e., nilotinib and dasatinib as
Fig. 1 Structural 3D model of Bcr-Abl catalytic domain. The ribbon
diagram of crystal structure shows the N-lobe at the top (dark gray)
and C-lobe at the bottom (green), rich in β-sheets and α-helices
respectively. The catalytic segment (yellow), the P-loop (red), the
activation loop (orange), and the hinge region (light blue) stand in the
middle. Key amino acidic residues are indicated in magenta circles:
Thr315 (T315) is the gatekeeper residue within the ATP-binding pocket
(black arrow), Asp363 (D363) is pivotal for nucleophilic attack on
peptide substrate during catalysis, Tyr393 (Y393) is the target of
phosphorylation that controls Abl activation and inactivation, whereas
the DFG (Asp-Phe-Gly) motif coordinates fundamental cofactors for
catalysis, namely Mg2+ ions [88]
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either first or second line of treatment, and bosutinib
as second line only [21].
Nilotinib (AMN107) shows greater potency and
effectiveness against almost the totality of resistance-
conferring mutations (see Table 1 for IC50 values),
except for T315I and few others, in newly diagnosed Ph+
CML patients [22, 23]. This result has been reached
starting from the structure of imatinib by inverting the
amide linking group, by replacing the piperazine ring with
3-methylimidazole, and by adding trifluoro-methyl group
to the anilinocarbonyl substituent, in order to increase the
number of VdW interactions (Fig. 4a). Therefore, ener-
getic contribution to the total of each H-b decreases,
avoiding impairment of inhibitor binding in case of muta-
tion of key residues involved in H-b interactions, although
the overall number of H-bs was kept unchanged. In spite
of these modifications, less stringent binding requirements
did not compromise selectivity and potency of nilotinib,
which conversely are even increased when compared to
those of imatinib (IC50 values of 10–25 and 100–500 nM,
respectively—see Table 1). As previously told, nilotinib is
active against DFG-out conformation only, and this
accounts for T315I resistance. Interestingly, nilotinib is
not substrate of neither influx transporter nor efflux
P-glycoprotein pump, unlike imatinib and, therefore, is
not sensitive to Bcr-Abl-independent mechanisms of
resistance [24].
Dasatinib (BMS-354825) is a peculiar DFG-in inhibi-
tor, even though it is not effective in the case of T315I
mutation [22]. Compared to imatinib, dasatinib enables
patients with chronic phase CML to achieve faster and
deeper treatment responses (i.e., median time to major
molecular response (MMR) for dasatinib arm was 15
versus 36 months for the imatinib arm, and BCR-ABL
transcript 4.5-log reduction was achieved by 17 versus
8% of patients by 24 months, respectively) [25]. Structur-
ally, the core phenyl ring has been replaced by an ami-
nothiazole group which occupies the adenine pocket of
Abl (Fig. 4b). The pyridine group of imatinib is instead
replaced by a hydroxyethyl piperazine, which remains
solvent-exposed also after Bcr-Abl binding. Dasatinib is
a smaller molecule than imatinib and it establishes less
interactions with its targets: nuclear magnetic resonance
studies have evidenced that dasatinib binds Bcr-Abl very
versatilely, in both active and inactive conformations
[26]. However, the free inactive DFG-out conformation
has a higher entropy than the active conformation: the
drop in entropy is less pronounced after dasatinib bind-
ing if the target is active, with enthalpy variation being
very similar in both conformations. Thus, free energy
Fig. 2 Asp363 protonation during catalysis. Here, the reaction mechanism of substrate phosphorylation is shown. The nucleophilic attack of
D363 on hydroxyl group of peptide substrate leads to its transient protonation that in turn causes conformational changes to inactive state.
(R = peptide substrate, D = aspartate, K = lysine, E = glutamate, S = serine)
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Fig. 3 Chemical optimization and functions of imatinib structure. The phenylaminopyrimidine derivative lead compound is indicated in black.① The
pyridyl group (red) added at 3′-position of the pyrimidine moiety enhanced cellular activity,② the amide substituent (blue) on the phenyl ring
provided the molecule with inhibitory activity against tyrosine kinases, and③ the 6-methyl (green) addition to the central aminophenyl ring nullified
the unspecific activity on PKC, thus increasing selectivity of the compound for Bcr-Abl. Finally,④ an N-methylpiperazine (purple) was added to enhance
aqueous solubility and oral bioavailability of the drug, but⑤ required the insertion of the amide linker and a benzene ring (yellow) as a spacer to
abolish the mutagenic potential of the aniline moiety otherwise obtained. Imatinib was therefore developed as optimized Bcr-Abl oral inhibitor
a b
c d
Fig. 4 a–d Structure comparison of Bcr-Abl clinically approved inhibitors. Chemical structures are here represented in color code with regard to
analogous groups of different tyrosine kinase inhibitors (green: core structure; red and blue: substituents group)
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decreases more in case of binding during DFG-in phase,
which is therefore preferentially inhibited by dasatinib,
because it is thermodynamically favored. Consequently,
several conformation-altering mutations, except for
T315I, are susceptible to dasatinib action, anyway [27].
Bosutinib (SKI-606) has a more different structure
(Fig. 4c), since it has been developed from a leading Src in-
hibitor compound (4-[(2,4-dichlorophenyl)amino]-6,7-di-
methoxy-3-quinolinecarbonitrile) [28]. The quinoline
central core required the addition of a hydrophilic proton-
able N-methylpiperazino moiety. Though it is not effective
against T315I mutation and does not show total selectivity
for Bcr-Abl (see Table 1), it has the important advantage of
being not efficiently excreted by multidrug resistance
transporters [29, 30]. Bosutinib is currently approved as
second-line treatment of CML [21]. Recent data suggest it
can be an important alternative to imatinib for previously
untreated patients with chronic phase CML, given its earl-
ier and higher rate of responses (47.2 and 36.9% of MMR
at 12 months for bosutinib and imatinib, respectively) [31].
Third-generation inhibitor: ponatinib
To date, the only approved third-generation TKI is
ponatinib (AP24534), a dual Src/Abl inhibitor designed
to especially overcome T315I mutation. In fact, isoleu-
cine in position 315 complicates Bcr-Abl switching to
inactive conformation and H-b formation with DFG-out
inhibitors. Nonetheless, ethynyl linkage of ponatinib has
indeed been inserted to accommodate isoleucine side
chain without any steric interference also in inactive
conformation (DFG-out) [32]. Structurally (Fig. 4d), it
nicely overlaps to nilotinib with only small differences
other than ethynyl linker: the methyl imidazole group is
replaced by a methyl piperazine moiety (like in imatinib).
Besides, instead of the pyridine-pyrimidine group of
nilotinib, ponatinib has a terminal imidazo[1,2-b]pyrida-
zin portion in the same position to optimize H-b forma-
tion within the hydrophilic pocket in which it gets
accommodated. Other bonds are similar to those of nilo-
tinib and so abundant that kinase point mutations have
less effect on the overall binding affinity and the potency
of the drug (see Table 1, ponatinib IC50 are the lowest
for almost every Bcr-Abl point mutation) [33]. Clinically,
all these structural modifications result in a high activity
in heavily pretreated patients with Ph+ leukemias with
resistance to other inhibitors, including patients with
T315I mutation, other mutations, or no mutations (in
[34], out of 43 patients with those characteristics, 98%
had a complete hematologic response, 72% a major cyto-
genetic response, and 44% a MMR). Moreover, ponatinib
has recently been demonstrated a valuable alternative to
allogeneic stem cell transplantation in patients with
T315I-positive advanced CML and Ph+ ALL [9].
Preclinically validated inhibitors: the targeted therapies of
tomorrow?
Other molecules have been effectively tested since the
advent of second-generation inhibitors, but have not en-
tered common clinical practice for neither CML nor
ALL, yet. Namely, they are bafetinib, rebastinib, tozaser-
tib, danusertib, HG-7-85-01, GNF-2 and -5, and 1,3,4
thiadiazole derivatives. Furthermore, it is highly probable
that new in silico and in vitro evidences may lead to new
molecules to enter the clinics in the near future to over-
come persistent resistances.
Bafetinib (INNO-406) development was aimed at ex-
tending the susceptibility spectrum of mutations to TKIs
and increasing selectivity towards Bcr-Abl to reduce
clinical adverse reactions during treatment, e.g., cardio-
vascular and metabolic toxicities of nilotinib [35]. That
was pursued by increasing hydrophobic properties of the
benzamide ring of imatinib (Fig. 5a): a trifluoro-methyl
group, similarly to nilotinib, was added to increase VdW
interactions in the abovementioned “hydrophobic cage”
[36]. In the meantime, in light of X-ray crystallography
predictions, the pyridine group of imatinib was replaced
by a more hydrophilic pyrimidine ring, thus increasing
aqueous solubility without impairing binding properties
and potency against Bcr-Abl (IC50 71 nM) [17]. Finally,
the dimethylaminopyrrolidine portion took the place of
the N-methylpiperazine ring, favoring H-b formation [36].
In this way, its activity is retained against several Bcr-Abl
mutants (submicromolar IC50, see Table 1), with the ex-
ception of a minority including T315I (IC50 > 10 μM) [37].
A phase I clinical trial evidenced that 19% of CML and Ph
+ ALL patients with imatinib resistance or intolerance
reached the complete cytogenetic response after bafetinib
as second-line treatment, suggesting its potential clinical
efficacy [38]. Differently from some solid tumors, a phase
II trial for CML and ALL is not ongoing, yet.
Rebastinib (DCC-2036) is a non-competitive con-
formational control inhibitor, designed to overcome
Abl gatekeeper mutations, mainly T315I, that impede
the occurrence of the DFG-out conformation and the
inhibitory action of both first- and second-generation
inhibitors [39]. It stabilizes a fundamental bond for
inactive conformation between Glu282 and Arg386,
regardless gatekeeper mutations. Structurally, the
fluoro-substituted phenyl central core, possessing a
ureic linker in ortho to the halogen atom, is also
bound to a carboxamide-substituted pyridine on one
side, and to a pyrazole, bearing 4-tert-butyl and
1-(6-quinolinyl) substituents, on the other side
(Fig. 5b). Crystallography evidenced that the ureic and
the carboxamide-pyridine groups establish five H-bs
mainly with the aforementioned Glu282 and Arg386
residues, whereas the rest of the molecule optimizes
VdW interactions with a hydrophobic cluster of
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amino acids, forcing out the DFG motif from the
catalytic site. In the case of T315I mutation, the
hydrophobic interactions are even enhanced, justifying
sensitivity to rebastinib in cellular assays with clones
displaying this mutation (IC50 13 versus 19 nM for
unmutated Abl) [40]. However, it is much less active
against P-loop E255V mutation (IC50 800 nM), possibly
due to destabilization of Bcr-Abl inactive confor-
mation, but its molecular mechanism deserves further
characterization [39]. Clinically, although rebastinib
showed efficacy (of 40 CML patients, 8 complete
hematologic responses were achieved, 4 of which had
a T315I mutation) [41], benefit has been considered
insufficient to justify continued development against
leukemias since the advent of ponatinib, to date.
Tozasertib (MK-0457, VX-680) is a pan-Aurora Kinase
inhibitor (IC50 4–27 nM) with activity also on Abl (IC50
10 nM) as ATP competitor [37, 42]. Peculiarly, Aurora
kinases are inhibited in their inactive state, whereas
Bcr-Abl, both WT and mutant T315I, in active conform-
ation [37]. Indeed, co-crystal structures evidenced four
H-bs established by the aminopyrazole pyrimidine in-
hibitor (Fig. 5c) with key residues of the ATP-binding
pocket, including Asp381 of the DFG motif when folded
in the ATP site. Neither bonds nor steric hindrance
occur between tozasertib and the gatekeeper residue, ac-
counting for vulnerability of both WT and T315I
Bcr-Abl (with IC50 of 30 nM) to this TKI [43]. All that
led to a phase II clinical trial evidencing benefit for
patients with T315I Bcr-Abl CML (44% had hematologic
responses), suggesting even more efficacy than ponatinib
for accelerated phase disease or as bridge therapy for
stem cell transplantation, given its higher myelosuppres-
sive effect [44]. Further developments or combinational
regimens seem to be amply justified for this promising
compound.
Danusertib (PHA-739358) is a multikinase inhibitor
with a selective spectrum extended to Aurora kinases,
Ret, TrkA, FGFR1, and Abl (IC50 of 13–79, 25, 31, 31,
and 47 nM, respectively) [45, 46]. Similar to dasatinib
and tozasertib, it is an ATP competitor for the active
form of Bcr-Abl, as evidenced by crystallographic data
[47]. Its pyrrolopyrazole core (Fig. 5d) provides three
H-bs with the hinge region of Abl, whereas the benzyl
group packs against Leu370 and the N-methyl-pipera-
zine sticks out the kinase pocket to be solvated. No key
interactions are established with the gatekeeper residue.
Therefore, danusertib binding mode accommodates the
T315I mutation, avoiding the steric clash that oppositely
occurs between first-/second-generation inhibitors and
the isoleucine 315 side chain. Actually, binding affinity
for T315I mutant is even higher than that for WT
Bcr-Abl (Kd 200 nM versus 2 μM, respectively [47]),
possibly due to increase in VdW interactions between
the inhibitor and the isoleucine residue. That accounts
also for the higher potency shown in cellular assays
against T315I mutant (IC50 120 vs 360 nM of WT Abl
[48]). Clinically, danusertib has shown acceptable
a
c d
f g
e
b
Fig. 5 a–g Structure comparison of Bcr-Abl preclinically validated inhibitors. Chemical structures are here represented in color code with regard
to analogous groups of different tyrosine kinase inhibitors (green: core structure; red and blue: substituents group)
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dose-dependent toxicities and promising activity in
advanced and resistant ALL and CML patients within a
phase II trial (4 out of 29 patients with accelerated or
blast phase CML responded, all 4 with T315I Bcr-Abl)
[49], paving the way for further preclinical and clinical
advancements.
HG-7-85-01 is a hybrid compound, designed by super-
position of nilotinib and dasatinib structures. The master
concept of condensing in a unique molecule the advan-
tages of a combinational therapy, i.e., overcoming resis-
tances, led to its first design and synthesis [50].
Structurally, the aminothiazole moiety of dasatinib is
condensed to a pyridine ring and the resulting portion is
linked to the phenyl-benzamide group of nilotinib
(Fig. 5e), conferring selectivity for DFG-out conform-
ation of Bcr-Abl. In fact, this structural arrangement re-
sults in a very accommodating inhibitor molecule for the
gatekeeper residue, showing activity also against T315I
Bcr-Abl in cellular assays (IC50 140 nM, less than three-
fold higher than for WT, i.e., IC50 58.5 nM [50]). Further-
more, the target selectivity spectrum is narrower than that
of ponatinib at a high-throughput screening [50, 51], sug-
gesting less adverse reactions than ponatinib at a clinical
level, especially those related to cardiovascular toxicity.
However, no clinical data are currently available, nor are
there ongoing trials, to the best of our knowledge.
Recently, new state-of-the-art molecules have been de-
signed and tested at a preclinical level to sensitize T315I
mutation to first and second-generation TKIs. Genetic,
nuclear magnetic resonance, crystallography, mutagenesis
and mass spectrometry studies identified GNF-2 (Fig. 5f)
and GNF-5 (its analogue bearing a N-(2-hyrdroxyethyl)
group at the amidic nitrogen atom) to be two allosteric
interactors of Bcr-Abl [52]. They bind the myristylation
site of C-lobe inducing a forced conformational change of
the kinase to inactive state, even if its gatekeeper residue
is mutated [53]. Co-administration of a classical inhibitor
with these compounds may therefore be effective also
against T315I mutant. However, mutations around the
myristate binding site, e.g., C464Y, P465S and V506L, are
known to induce resistance to GNF-2/5 activity, putatively
by steric hindrance (IC50 > 10 μM) [52]. This raises critical
issues on some compound mutations of Bcr-Abl, i.e., the
coexistence of different Bcr-Abl mutants in leukemic
clones of a same patient, which necessarily need to be tar-
geted by other approaches. Particularly, GNF-2 + dasatinib
(IC50 = 100 nM with 2 nM dasatinib concentration) and
GNF-5 + nilotinib (IC50 = 30 nM with 1 μM nilotinib con-
centration) resulted the most active and synergistic in
vitro combinations [52, 53]. Clinical translation of these
promising results could be found to be effective, especially
for Ph+ ALL patients, since they often present the p190
Bcr-Abl variant on which these compounds seem to be
more active.
A further way to inhibit Bcr-Abl could be paved by
1,3,4-thiadiazole derivatives, such as compound 2
(Fig. 5g), which emerged as putative DFG-in inhibitors
from an in silico screening by molecular docking simula-
tion studies [54]. Indeed, flexibility of its core is sup-
posed to allow several conformations of the substances
to bind the ATP site of Bcr-Abl active state [55]. As a
matter of fact, compound 2 proved to be a better
Bruton’s tyrosine kinase-inhibitor than imatinib (IC50 1
vs 7 μM), but predictions about affinity while testing
different substituents bound to the central thiadiazole
core may lead to the development of even more effective
Bcr-Abl inhibitors too, putatively also in the case of
resistance to classical TKIs [54].
Conclusions
Treatment of Ph+ CML and ALL has dramatically chan-
ged since the advent of targeted therapy against the
Bcr-Abl fusion protein at the turn of the twenty-first cen-
tury, and so the prognosis has done. The development of
targeted inhibitors started from a high-throughput screen-
ing to find out a leading pharmacophore that includes
compounds able to bind and block the chimeric kinase, by
impeding ATP binding in a competitive manner [16, 17].
After its rational development, according to
structure-activity relationship analysis and enzymatic as-
says [16], imatinib was optimized and rapidly approved for
the clinic [5]. Actually, the IRIS trial clearly demonstrated
that imatinib presented much higher effectiveness and re-
duced toxicity if compared to the standard of care of that
time, i.e., IFNα plus low-dose cytarabine regimen [56].
Although the radical increase in mean survival, new
mutations and forms of resistance came upon in com-
mon clinical practice [57], requiring further development
of inhibitors, similar to the process that led from the
parent compound to imatinib. By means of imatinib
modification or exploitation of totally different molecu-
lar scaffolds, several second- and third-generation TKIs
were developed. Some have already been approved for
clinic use, i.e., the second-generation nilotinib, dasatinib,
and bosutinib, and the third-generation ponatinib,
whereas other still need clinical validation, e.g., bafetinib,
rebastinib, tozasertib, danusertib, HG-7-85-01, GNF-2
and GNF-5, and other 1,3,4-thiadiazole derivatives. The
onset of new mechanisms of resistance, both Bcr-Abl
dependent and independent, requires always new thera-
peutic strategies to be improved, in order to guarantee
increasingly higher survival rates. Therefore, this con-
tinuous challenge makes the topic discussed in the
present review undoubtedly up-to-date. Interestingly,
most of the studies so far reported were carried out with
high-throughput screening, cellular and enzymatic as-
says, crystallography, nuclear magnetic resonance, mass
spectrometry, and in silico predictions to determine
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selectivity spectrum, activity against mutations, and
bioavailability of the new inhibitors in view of clinical
translation. Noteworthy, these approaches can be
applied to other targeted therapies facing specific
resistance-conferring mutations in different models,
e.g., T790M mutation of epidermal growth factor
receptor (EGFR) against gefitinib [58] or several
anaplastic lymphoma kinase (ALK) point mutations
against crizotinib [59].
The increasing number of approved and experimental
inhibitors is slowly approaching the therapeutic solution
of single specific mutations of Bcr-Abl, which were also
highly deadly until recent past, e.g., T315I; nevertheless,
compound mutations are a further emerging hurdle in
the clinic, with only little knowledge about their prog-
nostic and therapeutic meaning, to date [60]. Indeed,
they may need innovative approaches to be dealt with,
such as combination therapies, reevaluating discarded
TKIs (in light of new therapeutic demands) or molecules
with wider spectrum of targets, e.g., danusertib. In light
of this, strategies other than Bcr-Abl targeting may be
successfully exploited against refractory diseases, as re-
cently evidenced for IL-15-mimetic ALT-803,
Hsp90-inhibitor ganetespib, HDAC-inhibitor panabino-
stat, Ras-antagonist rigosertib, β-catenin-antagonist
PRI-724, and MELK-inhibitor OTS167, reviewed else-
where [61]. Moreover, the hurdle of developing thera-
peutic monoclonal antibodies against CML may be
overcome by evolving promising detection tools, as TPγ
B9-2 towards protein tyrosine phosphatase receptor
gamma (PTPRG) [62].
Another caveat that should be kept in mind is that
probably “CML not always simply relies on t(9,22) Ph
chromosome”: diverse translocations that activate Abl or
other oncoproteins alternatively underlie very poor prog-
nosis due to inefficacy of Bcr-Abl inhibitors [63, 64].
Conversely, other diseases characterized by hyperactivity
of tyrosine kinases, such as PDGFRα in gastrointestinal
stromal tumor (GIST) and hypereosinophilic syndrome
or c-Kit in systemic mastocytosis, can benefit from ima-
tinib and other inhibitors with wide selectivity spectrum
[65]. Importantly, the mutational state of these kinases
can drive the choice towards the most proper inhibitor:
the commonly occurring imatinib-resistant PDGFRα
D842V and c-Kit D816V mutants in GISTs and mastocy-
tosis, respectively, are more strongly inhibited in vitro by
dasatinib rather than imatinib (IC50 62 vs 642 nM and
37 nM vs 3.8 μM, respectively—see Table 1 for these and
other mutations), even though clinical benefits of dasati-
nib had been demonstrated only for the former [66].
However, the same therapy may work differently for di-
verse diseases, even if caused by similar genetic re-
arrangement: CML and Ph+ ALL are usually due to
different Bcr-Abl forms, i.e., p210/p230 and p190,
respectively [67]. Actually, it has been reported that
p190 and p210 have at least partially independent signal-
ing cascades that are mediated by differential
protein-protein interactions, which may help explain the
observed association of p190 with Ph+ ALL and p210/
p230 with CML. Notably, the differential signaling net-
works of Bcr-Abl p210 and p190 kinases in leukemia
cells have very recently been identified by functional
proteomics, e.g., demonstrating a strong and preferential
binding of AP2 complex, a major regulator of
clathrin-mediated endocytosis, with p190, whereas
Bcr-Abl is likely to be inhibited by p210-selective inter-
actor Sts2 tyrosine phosphatase [68].
All that may also account for different therapeutic
efficacy of specific inhibitors, as noticed while describing
GNF modulators previously in the main text of this
review.
Overall, the developmental process of Bcr-Abl inhibi-
tors perfectly exemplifies an important concept of bio-
medical research: translational medicine, aimed at lading
scientific breakthroughs from bench to bedside, drove
the development of imatinib starting from the identifica-
tion of target and pharmacophore; nonetheless, the more
innovative concept of reverse translational medicine,
aimed at turning “bedside” problems to “bench” ones,
has been followed during the rational development of
second- and third-generation TKIs to effectively override
the progressive onset of resistances and adverse drug re-
actions in the clinic.
In the context of tumor therapy, those lessons learned
from Bcr-Abl inhibitors serve both as a model to over-
come the still open issues about CML and Ph+ ALL and
as a proof of concept for rationally developing novel
small molecules against specific tumor types.
Finally, imatinib history may serve as a milestone of
the developmental process of any inhibitor, driving drug
discovery towards future chemotherapy-free and
target-oriented treatments.
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